INTRODUCTION
Crohn's disease is characterized by chronic transmural inflammation of the bowel. It can involve any portion of the gastrointestinal tract and is associated with serious complications, including bowel strictures, abscesses, fistula formation, and perforation. As neither medical nor surgical therapy provides a cure for Crohn's disease, the primary goals of therapy are to induce and maintain remission and prevent complications.
Treatment for Crohn's disease usually involves drug therapy or, in certain cases, surgery. Medical therapies include aminosalicylates, corticosteroids, immunosuppressants, and biologic agents. 1 As a biologic agent, infliximab, a monoclonal antibody to tumor necrosis factor (TNF), is indicated for refractory luminal and fistulizing Crohn's disease that does not respond to other medical therapies or surgery. 2, 3 Additionally, infliximab therapy increases mucosal healing and decreases the need for hospitalization and surgery. However, after one decade of experience with this potent anti-TNF ther- apy, it seems appropriate to evaluate the associated safety issues. 4, 5 A retrospective observational study reported that infliximab may be a risk factor for free perforation in Crohn's disease; 6 Association functional class III/IV heart failure. 13, 14 Recently, Eshuis et al. 6 reported that anti-TNF treatment for Crohn's disease was associated with a significantly higher rate of free perforation requiring surgery. Although there was an attempt to equate the disease activity between cases and controls, it was quite clear that the disease activity comparison was poorly quantified. Therefore, the study demonstrated only a significant association between the occurrence of free perforation in Crohn's disease patients and the use of anti-TNF therapy, but did not prove a cause-and-effect relationship. However, the current report is the first case presentation describing free perforation in Crohn's disease patients after infliximab treatment and strongly suggests that infliximab may be a risk factor for free perforation in Crohn's disease, especially in cases with severe strictures.
Greenstein et al. 10 suggested that increased intraluminal pressure proximal to the stricture and ischemia due to in- In the current case, free perforation was likely caused by rapid and markedly increased intraluminal pressure proximal to the severe strictures, secondary to a large amount of food intake over a short time due to the therapeutic effectiveness of infliximab and relief of inflammation of the intestinal wall due to the effects of the drug. Previous studies have reported that cytokines, such as TNF-α, can influence human behavior during inflammatory conditions. Changes in behavior include decreased sexual drive, increased sleepiness, decreased appetite, and fatigue. 15, 16 Infliximab decreases the amount of circulating TNF-α, which is increased in Crohn's disease and, as a result, may influence behavior in Crohn's disease. 17 Therefore, infliximab might contribute to overeating. In general, disease-associated fibrous reactions and adhesions to adjacent organs appear to be protective against free perforation. If a minimal perforation does occur, then either an abscess will develop within the inflammatory mass or a fistula to an adjacent organ will develop. But in the current case, infliximab blocked the inflammatory response as a "treatment" effect, and contributed to the occurrence of free perforation by preventing the formation of an inflammatory mass to seal off the imminent perforation.
This case report and discussion emphasize that during or after infliximab treatment for Crohn's disease accompanied by severe strictures, a large food intake should be avoided.
Although food tolerance is an important signal of treatment effectiveness, slow and incremental increases in intake are advised.
